However, CD3–Fas–CAR-T cells, which lacked both Fas and B2M, outperformed other modifications in controlling leukaemia growth in mice, even under immune rejection by both NK cells and T cells, underscoring an innovative strategy for addressing the challenges of GVHD in CAR-T cell therapy [238]. This evidence concerns the gene FAS and graft versus host disease.